TDCS for parkinson‘s disease disease-related pain: A randomized trial
González-Zamorano et. al, 2024. Clinical Neurophysiology.
- This triple-blind randomized controlled trial included twenty-two patients (age range 38–85, 10 male) with PD-related pain. Eleven subjects received ten sessions of 20 minutes tDCS over the primary motor cortex contralateral to pain at 2 mA intensity. Eleven subjects received sham stimulation.
- The active-group showed significant improvements over the sham-group after 15 days (p = 0.017).
- tDCS alleviates perceived pain, reduces pain sensitization and increases descending inhibitory systems in Parkinson’s disease patients.